Innovation Driving Opportunities For Active Transdermal Drug Delivery Analysis By Greystone Associates Reveals Market And Technology Factors
To expand the limits of transdermal drug delivery, developers are employing energy sources such as ultrasound, heat and electrical current to affect active transport through the skin. Another approach is the modification or removal of surface skin layers, a group of technologies collectively referred to as microporation, which can be used alone or in conjunction with energy-enabled devices to expand the size and type of drug molecules capable of transdermal delivery. These techniques can increase the upper molecular size limit dramatically, opening up a host of opportunities for transdermal delivery.
These findings are examined in a new and comprehensive survey written and researched by Greystone Associates. The survey concludes that to take full advantage of these evolving dynamics, active transdermal delivery participants must deal with a number of economic and market forces influencing the way drug companies develop and commercialize their products. Success will favor those sector participants willing to incorporate patient-centric design features and drug-device combination engineering paradigms into their product development programs.
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Greystone Associates
Inovare de conducere de ºanse pentru active Transdermal livrare de droguri de analizã de cãtre asociaþi Greystone relevã factorii de piaþã ºi tehnologie - Innovation Driving Opportunities For Active Transdermal Drug Delivery Analysis By Greystone Associates Reveals Market And Technology Factors - articole medicale engleza - startsanatate